Given the therapeutic potential of LOX/LOXL2 inhibitors in diabetic nephropathy, we conducted structure-based virtual screening of a natural product library (123 compounds derived from renal-protective botanical medicines) against LOX/LOXL2 using molecular docking to prioritize high-affinity candidates (Figure 6(a)). The gene discussed is LOXL2; the disease is diabetic kidney disease.